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Introduction: In vaccine development, dose-response curves are commonly assumed to be saturating.
Evidence from tuberculosis (TB) vaccine, H56 + IC31 shows this may be incorrect. Mathematical mod-
elling techniques may be useful in efficiently identifying the most immunogenic dose, but model calibra-
tion requires longitudinal data across multiple doses and time points.
Aims: We aimed to (i) generate longitudinal response data in mice for a wide range of H56 + IC31 doses
for use in future mathematical modelling and (ii) test whether a ‘saturating’ or ‘peaked’ dose-response
curve, better fit the empirical data.
Methods: We measured IFN-c secretion using an ELISPOT assay in the splenocytes of mice who had
received doses of 0, 0.1, 0.5, 1, 5 or 15 lg H56 + IC31. Mice were vaccinated twice (at day 0 and 15)
and responses measured for each dose at 8 time points over a 56-day period following first vaccination.
Summary measures Area Under the Curve (AUC), peak and day 56 responses were compared between
dose groups. Corrected Akaike Information Criteria was used to test which dose-response curve best fit-
ted empirical data, at different time ranges.
Results: (i) All summary measures for dose groups 0.1 and 0.5 lg were higher than the control group
(p < 0.05). The AUC was higher for 0.1 than 15 lg dose. (ii) There was strong evidence that the dose-
response curve was peaked for all time ranges, and the best dose is likely to be lower than previous
empirical experiments have evaluated.
Conclusion: These results suggest that the highest, safe dose may not always optimal in terms of
immunogenicity, as the dose-response curve may not saturate. Detailed longitudinal dose range data
for TB vaccine H56 + IC31 reveals response dynamics in mice that should now be used to identify optimal
doses for humans using clinical data, using new data collection and mathematical modelling.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccines are one of the most important and cost-effective inter-
ventions in public health [1]. However, development from vaccine
discovery to licensure is costly; in the region of US$0.8 billion [2].
Mistakes in vaccine development may cause not only a waste of
resources (both financial and experimental) but also ultimately,delay licensure of an effective vaccine. A key decision in develop-
ment is vaccine dose amount (hereafter dose), which, if chosen
optimally would achieve maximum vaccine efficacy, with minimal
side effects.
It is common practise in pre-clinical and clinical trials that vac-
cine dose is increased incrementally until a maximum safe dose
that promotes an effective response (usually an antibody response)
is achieved; it is assumed that this response will then saturate [3].
This saturating relationship between dose and host response has
been the standard assumption in vaccine development and many
vaccines have proceeded through to the late stages of development
with this method as a basis for dose choice [4,5].
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clinical studies in mice with the IC31 adjuvanted fusion protein
TB10.4 /Ag85B (H4) revealed that low antigen doses were both
more immunogenic and provided increased protection relative to
high doses [6]. In accordance, a clinical study showed that
responses after vaccination with the same H4 + IC31 vaccine were
not different between the 5 and 15 lg doses, decreased at 50 lg
and were minimal for the 150 lg dose [7]. In a latently infected tar-
get population, vaccination with an analogous vaccine H56 (an
ESAT-6/Ag85B/Rv2620 fusion protein vaccine) also adjuvanted
with IC31 (H56 + IC31) showed that out of two doses tested in
Quantiferon-positive (QTF+) individuals, the lowest dose (15 lg
H56 + IC31) was more effective at inducing polyfunctional CD4+
T cell responses than the higher dose (50 lg H56 + IC31) [8]. Of
note, the higher dose (50 lg) of the related first-generation Hybrid
vaccine H1 + IC31 was taken forward to a First-in-man study,
which may have led to suboptimal vaccine evaluation [9].
Although immunogenicity not only depends on antigen dose, but
indeed also on the type and nature of the adjuvant employed,
the incorrect assumption that a higher dose is preferred per se
for protein vaccines (or other platforms) has further been brought
into question by vaccines using other types of adjuvants [10].
Translational quantitative analysis methods to inform dose
decision-making already exist in the drug development world. Ph
armacokinetic/Pharmacodynamic (PK/PD) modelling uses mecha-
nistic mathematical methods to describe how dose influences drug
dynamics over time [11,12]. Translational modelling to predict
human PK/PD parameters based on animal data is a key stage in
model-based drug dose decision-making [12–14], and is often
required by regulators during development. Although pharmacoki-
netic data is often not available for vaccines, pharmacokinetics is
dependent on dose and regimen, and thus analogies to dose finding
for vaccines are relevant. No translational quantitative methods
are applied in vaccine development, as the chosen vaccine dose
to be tested in a clinical environment is usually based on qualita-
tive assessment of the pre-clinical data [15], which has the poten-
tial to ignore or underutilise dose-response information.
To address this gap, we are proposing the new field of Immunos
timulation/Immunodynamic (IS/ID) modelling, analogous to that of
PK/PD modelling, to make more informed human vaccine dosing
decisions based on animal response data. In this field, models will
be created to describe the underlying mechanisms that determine
the immune response dynamics (immunodynamics) following vac-
cination, e.g. the influence of the innate and regulatory systems for
T cell expansion and contraction (immunostimulation). These
models will then be calibrated to dose ranging data from animals
and model parameters ‘‘mapped” to known human response data.
Subsequently, dose-response curve in humans can be predicted,
providing information on the most effective range of doses to be
first evaluated in clinical trials. In this larger body of work, we will
apply these methods on the aforementioned TB vaccine, H56
+ IC31 by measuring IFN-c after vaccination over time.
As in model-based drug development, extensive longitudinal
data are required. Published data on a wide dynamic range of doses
and time points do not exist for H56 + IC31, where dose-ranging
studies have only ever been conducted on minimal pre-specified
time points [6]. As such, we conducted and report here an experi-
ment in which we vaccinated mice with a wide range of doses of
H56 + IC31 and measured responses extensively over time. These
data outlined in this paper will be used in future IS/ID modelling
to further our knowledge in mice, non-human primates and
humans. In this paper, we aim to (i) generate longitudinal response
data in mice for a wide range of H56 + IC31 doses for use in future
mathematical modelling and (ii) test whether a ‘saturating’ or
‘peaked’ dose-response curve, better fit the empirical data.2. Materials and methods
2.1. Ethics statement
All animal work was carried out in accordance with the Animals
(Scientific Procedures) Act 1986 under a license granted by the UK
Home Office (PPL 70/8043), and approved by the LSHTM Animal
Welfare and Ethics Review Body.2.2. Animals
Female CB6F1 mice were acquired from Charles River UK at 6–
8 weeks of age. Animals were housed in specific pathogen-free
individually vented cages, were fed ad libitum, and were allowed
to acclimatize for at least 5 days before the start of any experimen-
tal procedure.2.3. Vaccination
The experimental vaccine H56 (comprising Mycobacteria tuber-
culosis antigens Ag85B-ESAT-6-Rv2660c [16], provided by Statens
Serum Institute (SSI), Copenhagen, Denmark) was formulated in
IC31 adjuvant (provided by SSI on behalf of Valneva Technologies)
and 10 mM Tris-HCl buffer (pH 7.4) as described in [17] to obtain a
final volume of 200 ll/mouse. The adjuvant IC31consists of a mix-
ture of the cationic peptide KLK (NH2-KLKL5KLK-COOH) and the
oligodeoxynucleotide ODN1a (oligo-(dIdC)13). Adjuvant doses
were 100 nmol peptide and 4 nmol oligonucleotide for every vac-
cine (H56) dose. Antigen doses of 0.1, 0.5, 1, 5 or 15 lg of H56
+ 100/4 nmol IC31 (hereafter, H56 + IC31) were administered per
animal at day 0 and 15, the same dose was used at both vaccination
times within a group. Control animals received no vaccination. The
vaccine was administered subcutaneously into the left or right leg
flap.2.4. IFN-c ELISPOT
IFN-c secreting CD4+ T cells were measured using the ELISPOT
assay. Single cell suspensions of mouse splenocytes were prepared
by mechanical disruption of spleens through a 100 lm cell strainer
on the day of sacrifice. After lysis of red blood cells, single cell sus-
pensions were made up in antibiotic-free media [RPMI-1640
(Sigma-Aldrich, Dorset, UK) + 10% heat-inactivated FBS (Labtech
International Ltd, Uckfield, UK) + 2 mM L-Glutamine (Fisher Scien-
tific, Loughborough, UK)]. 96-well microtiter ELISPOT plates
(MAIPS4510, Millipore, Watford, UK) were coated with 10 lg/ml
rat anti-mouse IFN-c (clone AN18, Mabtech, Nacka Strand, Swe-
den). Free binding sites were blocked with RMPI 1640 supple-
mented as described above. 2.5  105 of total splenocytes were
added and incubated in duplicate with H56 (10 lg/ml), supple-
mented RPMI as a negative control, or Phorbol myristate acetate
(PMA) (50 lg/ml, Sigma-Aldrich) and Phytohemagglutinin (PHA)
(10 lg/ml, Sigma-Aldrich) as a positive control. After 24 or 48 h
of incubation at 37 C in 5% CO2, IFN-c was detected with 1 lg/
ml biotin labelled rat anti-mouse antibody (clone R4-6A2, Mab-
tech) and 1 lg/ml alkaline phosphatase-conjugated streptavidin
(Mabtech). The enzyme reaction was developed with BCIP/NBT
substrate (5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetra-
zolium) (MP Biochemicals, UK) and stopped by washing the plates
with tap water when individual spots could be visually detected
(up to 5 min). ELISPOT plates were analysed using an automatic
plate reader. IFN-c-specific cells are expressed as number of
spot-forming units (SFU) per million spleen cells after non-
specific background was subtracted using negative control wells.
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ELISPOTs were carried out at 2, 7, 9, 14, 16, 21, 28, and 56 days
after the first vaccination for all doses. Five mice were used per
time point per dose group (equating to 40 mice in a dose group
from initiation to conclusion of the experiment). This schedule
was designed to reflect the H56 + IC31 phase I clinical trial sched-
ule [8] and previous experimental schedules in mice using the H-
series vaccines by SSI in CB6F1 mice [6,16,18,19].2.6. Statistical methods
2.6.1. Summary of IFN-c response data after two vaccinations with TB
vaccine H56+IC31 for future mathematical modelling
The Wilcoxon test was used to test for differences in IFN-c
responses generated as a result of the two ELISPOT incubation
times (on data pooled across dose groups and time points). The fol-
lowing summary measures were used to quantify responses over
time: Area Under the Curve (AUC), day 56 response, peak response
between first and second vaccination and peak response post-
second vaccination (peaks may occur at different times as they
were defined as the highest median response measured in the
respective time period). As IFN-c responses over time within a
dose group were not dependent (each taken from an individual
mouse spleen), AUC was calculated using 200 samples of the pos-
sible combinations of the five mice per dose group over time. Full
details of this method are outlined in Supplementary material and
Fig. S1. The non-parametric Dunn test was used to compare the
summary measures between the dose groups and a Bonferroni cor-
rection applied to account for comparisons across multiple groups.
A p-value < 0.05 was considered significant.2.6.2. Determine the shape of dose-response curve when examined at
varying sample times and the best dose predicted by fitted curves
To assess the shape of the dose-response curve (IFN-c SFU per
million splenocytes versus dose), a saturating or peaked curve
was fitted to all IFN-c responses against the (log10 transformed)
doses using nonlinear regression, in the software Prism (v 7 for
Mac, GraphPad Software, California USA, www.graphpad.com).
Briefly, the aim of nonlinear regression is to find the parameters
that minimise the sum of the squared residuals from all data points
to the curve (see Supplementary material for description). We
choose a sigmoidal equation as the saturating curve and the
gamma probability density function (pdf) as the peaked curve
(see Supplementary for equations). The choice of the gamma pdf
was due to the hypothesis that the dose response, once peaked,
will not increase again and will never decrease to a zero response.
To establish which of the shapes best described the dose-response
curves the goodness-of-fit measure, the corrected Akaike informa-
tion criteria (AICc) was compared, where a lower AICc indicates a
better fit. A difference in AICc value between curve fits of greater
than seven was considered strong evidence of a better fit and a dif-
ference in AICc of greater than ten was considered absolute evi-
dence of a better fit [20] (Table S1). To assess how the dose-
response curve changed with time, the response data was pooled
into three time ranges: between the first and second vaccination
(day 2, 7, 9, 14 aggregated), post-second vaccination (day 21, 28
and 56 aggregated) and day 56 responses. The best dose was
defined as the dose that produced the maximum IFN-c response
as predicted by the fitted curves.3. Results
3.1. Summary of IFN-c response data after two vaccinations with TB
vaccine H56+IC31 for future mathematical modelling
Splenocyte-derived IFN-c responses did not differ for the 24
versus the 48 h ELISPOT incubation times when responses where
pooled over all dose groups and time points (p-value = 0.67,
Fig. S2). Therefore, an incubation time of 24 h was used in the fol-
lowing analyses.
The IFN-c responses over time for each dose group are shown in
Fig. 1 (significance of the changes in dynamics over time are in
Table S2). Out of the samples taken to calculate the AUC, the com-
mon significance trend showed that dose groups 0.1, 0.5 and 1 lg
had significantly higher AUC than the control group, and the dose
group 0.1 lg had significantly higher AUC than dose group 15 lg
(Fig. 2, Table S3). Peak responses between first and second vaccina-
tion were significantly higher in the dose groups 0.1, 1, 5 lg than in
the control group and for post-second vaccination, dose groups 0.1,
0.5 and 5 lg were significantly higher than the control group
(Figs. 1 and 2, Table 1). Similarly, day 56 responses were signifi-
cantly higher for the dose groups 0.1, 0.5 and 1 lg than the control
group and the dose group 0.5 lg was higher than 15 lg. However,
this did not reach statistical significance (Figs. 1 and 2, Table 1). For
all summary measures, no other comparisons between dose groups
were statistically significantly different (Fig. 2, Table 1).3.2. Determine the shape of dose-response curve when examined at
varying sample times and the best dose predicted by fitted curves
To establish the shape of the dose-response curve (IFN-c SFU
per million splenocytes versus dose), we fitted either a saturating
or peaked function for three time ranges. There was strong evi-
dence that the peaked curve was a better fit to the response data
between first and second vaccination (Fig. 3A, Table S4) with a AICc
difference of 7.5 favouring the peaked (gamma) curve. The AICc
difference was 18.8 and 10.9 for the post-second vaccination
(Fig. 3B, Table S5) and day 56 (Fig. 3C, Table S6) response data, sug-
gesting absolute support for the peaked curve for both these time
ranges. The best dose predicted by the peaked fitted curve for the
time ranges; between first and second vaccination, post-second
vaccination and day 56 were 0.026, 0.11 and 0.25 lg, respectively
(transformed from log10 scale, Fig. 3). Due to the right-skewed nat-
ure of the responses the best saturation curve had an almost
immediate increase followed by immediate plateau for all time
ranges (Fig. 3). As such it was not possible to obtain a best pre-
dicted dose using the saturation model as, in this case, all doses
generated the same response.4. Discussion
Our future aim is to apply the new field of Immunostimulation/
immunodynamic (IS/ID) modelling to translate vaccine dose-
response information between animals and humans and thus
quantitatively inform vaccine dose decision-making. To begin ini-
tial examination of such methods, we conducted a longitudinal
dose-ranging experiment of the novel TB vaccine H56 + IC31 in
mice, and a mathematical analysis of the dose-response curve over
time.
We successfully generated an intensive time course of IFN-c
response data to vaccination where AUC and peak analysis showed
a trend toward higher responses over time in the lower doses than
in the higher doses. By using mathematical curve fitting, we
showed that the IFN-c dose-response follows a peaked shape
instead of the commonly assumed saturation shape for all time
Fig. 1. Median IFN-c responses (horizontal black bars) and responses of individual mice per time point (blue points) for each dose. As the control group did not receive H56
+ IC31, the median of all responses from the control group (which did not significantly change throughout the experiment) was used to represent all mice at baseline. The
Wilcoxon test was used to compare consecutive time points, where ⁄equates to p-value < 0.05 and ⁄⁄p-value < 0.01 (Table S2). (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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trended toward that curve shape after the first dose. Using the
peaked fitted curve, we were able to determine which dose may
provide the maximal predicted IFN-c response in mice. Our results
indicate this was at a low range; between 0.02 and 0.25 lg H56
+ IC31. It must be noted that, there is uncertainty associated with
our predictions for best dose which is apparent in Tables S4–S6,
where the standard error was high for some gamma distribution
function parameters, particularly for the time ranges between first
and second vaccination and post-second vaccination. This is poten-tially due to a lack of response information between dose 0 and
0.1 lg, which would provide information on the increase of the
peaked curve. Despite this, as we show a definitive decline in the
dose-response at the higher dose range (approximately after dose
1 lg H56 + IC31), our predicted best dose range show compelling
evidence that lower doses than previously explored in mice using
very similar vaccines [6,16,18,21,22], would be preferential. Impor-
tantly, as previous evidence suggest the human dose-response may
be of a similar shape for the H-series of vaccines from SSI [7,8]
(although higher in magnitude), this implies that previously tested
Fig. 2. AUC calculated from number of IFN-c secreting CD4+ T cells after two vaccinations with H56 + IC31 from individual mice spleens, number of IFN-c secreting CD4+ T
cells between first and second vaccination, after second vaccination and day 56 by dose (lg H56 + 100 nmol IC31). Dose 0 equates to the control group. The plot for AUC is
representative of the 200 samples taken to establish statistical differences in AUC by dose (see methods). X axis not to scale.
Table 1
Median (IQR) values for the summary measures day 56 response, peak between first and second vaccination and post-second vaccination IFN-c responses by dose. Significance in
the summary measures was tested between dose groups using the non-parametric Dunn test with a Bonferroni correction. Those comparisons between dose groups with a p-
value < 0.05 or 0.05 < p-value < 0.1 (starred) are displayed. Abbreviations: IQR = interquartile range, vacc = vaccination.
Dose group (lg
H56 + IC31)
Median day 56
response (IQR)
Significantly
different from dose
Median Peak between 1st
and 2nd vacc (IQR)
Significantly
different from dose
Median Peak post
2nd vacc (IQR)
Significantly
different from dose
Control 10 (2–14) 0.1, 0.5, 1 18 (4–18) 0.1, 1, 5 44 (26–64) 0.1, 0.5, 5
0.1 298 (208–538) Control 182 (152–206) Control 590 (464–652) Control
0.5 352 (338–446) Control, 15⁄ 156 (118–168) – 414 (322–592) Control
1 302 (198–308) Control 146 (110212) Control 488 (104–520) –
5 106 (86–188) – 124 (106–296) Control 502 (456–586) Control
15 94 (76–96) 0.5⁄ 124 (22200) – 246 (130–248) –
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optimal response in terms of immunogenicity.
We use the frequency of IFN-c secreting CD4+ T cells measured
using the ELISPOT assay as our chosen immune response readout
to reflect the current convention in TB vaccine development for
dose selection. IFN-c is a cytokine shown to be associated with
control of infection or decreased risk of TB disease [23], however
these findings have been a topic of controversy in TB vaccine devel-
opment [24]. In previous work by Aagaard et al. in the vaccine H4
+ IC31, results showed that mice vaccinated with a lower dose
(0.5 lg H4) experienced significantly higher IFN-c responses than
higher doses (5 and 15 lg H4) and, significantly stronger protec-
tion against Mtb. infection (measured by Mtb. colony forming
units) than the higher doses, in two independent challenge exper-iments [6]. These results support our choice of IFN-c as a readout.
We also compliment Aagaard et al.’s study by measuring the IFN-c
response at multiple time points, thus assessing trends in the dose-
response curve over time.
It is possible that varying dose may alter the function or type of
CD4 T cell secreting IFN-c, which the ELISPOT assay will not detect.
Further lab assays such as flow cytometry should be used in the
future work to determine the function or type of cell produced as
a result of varying dose, which may then be used in clinical trials
for human dose selection.
Dose concentration feasibility and animal cost and overall num-
bers limited the size of our study. By testing in larger groups of
mice at potentially fewer time points, we may have gained greater
certainty in response differences and fitted dose-response curves.
Fig. 3. Results of the dose-response curve fitting analysis for the time ranges (A) between first and second vaccination (aggregated responses from days 2, 7, 9 and 14), (B)
post-second vaccination (days 21, 28 and 56) and C. Day 56 (last time point). Black points correspond to the number of IFN-c secreting CD4+ T cells from one mouse spleen in
response to vaccination for the relevant time range, red diamonds show the mean of the responses, the black solid lines are the peaked (gamma) fit, the black dashed line
show the saturating (sigmoidal) curve fit and the vertical green line indicated the best dose as predicted by the peaked curve fit. The table shows the differences in AICc for A,B
and C between the saturating and peaked curve fits. The x-axis is log10(dose: lg H56 + IC31) + 2 to transform the dose to a log scale and to ensure positivity, but x-axis labels
show the non-logged value for clarity (to avoid infinite values, control (dose 0) is not logged).
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detailed dynamics of the vaccine response and dose-response
curves over time, since this has been performed infrequently in
the past. We believe a higher maximum dose may have better
defined the decline in the dose-response curve. As the size of the
study was limited, we concentrated efforts on the lower doses,
where previous exploration is lacking; however, we found that
the probable best dose is still lower than the minimum dose used
here.
We have identified the following areas for further research. The
mathematical curve fitting we conducted has provided the basis
for further optimised studies in animals, i.e. we now know that
the dose range that captures the probable best dose should be 0–
0.3 lg H56 + IC31 (based on our predicted best dose values) not
the initial 0–15 lg H56 + IC31 (a reduction of 98% in the range).
Expanding the dose range in the lower end between 0 and 0.1 lg
will further increase our best dose predictions, as the peaked curve
parameters will be estimated with greater certainty. This warrants
further animal studies to investigate in greater detail the host
response to low dose vaccination.
Additionally, we used AUC to quantify the magnitude of the
immune response for the duration of the experiment and com-
pared AUC between dose groups. However, we do not interpret this
measure as the cumulative immune response over time, as would
be appropriate in drug AUC measures, but an indication of overall
higher immune response magnitude. In vaccine development, dosedecisions are made based on the dose response curve at one time
point (usually a long-term time point) and as such it would be
advantageous to know how dose effects the dynamics of the
immune response that may lead to higher average response in
the long-term. As such, our future aim is to apply the new field
of Immunostimulation/immunodynamic (IS/ID) modelling, where
by a mechanistic mathematical model incorporating the funda-
mental T cell subsets involved in a Th1 immune response will be
calibrated to the ELISPOT or another given measure over time.
The IS/ID model will allow us to quantify how the dynamics of
the immune response differ between dose groups (and across the
entire mouse population) by assessing the change in model param-
eters by dose. To achieve this, we will use the robust statistical
framework, Nonlinear Mixed Effects Modelling to calibrate the
model to the data and characterise the parameters and associated
parameter variation. IS/ID modelling will also be used to translate
vaccine dose-response information between animals and humans.
To achieve this we will utilise known allometric scaling factors for
H56 + IC31 between mouse and human we aim to ‘‘map” IS/ID
model parameters from one dose of the outlined experiment to
existing human H56 + IC31 dose data (one dose 50 lg H56
+ 500 nmol IC31). The effect of heterogeneity in target human pop-
ulations (due to HIV status, existing latent infection, etc.) on IS/ID
modelling parameters will be taken into account. Following this
mapping, we can then use the remaining doses to predict the dose
response curve in humans. This predicted human dose response
S.J. Rhodes et al. / Vaccine 34 (2016) 6285–6291 6291curve will be used as a guide to select further doses to test in clin-
ical trials.
Additionally, as the antigen dose-response may also vary with
the adjuvant dose and type of adjuvant, in order to fully charac-
terise and optimise complete vaccine (H56 + IC31) dose it would
be necessary to perform a checkerboard interaction pattern, the
design of which could be informed by IS/ID modelling through
optimal design analysis [25].
5. Conclusion
Our results suggest that the highest, safe dose is not always
optimal in terms of host response as the dose-response curve is
not saturating, which may also be true for vaccines against dis-
eases other than TB. Mathematical modelling can be used on the
detailed longitudinal dose range data for TB vaccine H56 + IC31
to simulate responses to optimise further experiments in mice
and help to identify optimal doses for humans.
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